Eric Jon Schlote
Fairway
Summary
Results-driven professional prepared to lead and inspire teams towards achieving organizational goals. Extensive experience in developing and executing strategic initiatives that drive growth and operational excellence. Strong focus on team collaboration and goal achievement, adaptable to changing business needs. Skilled in strategic planning and financial management.
Overview
24
24
years of professional experience
Work History
Chief Executive Officer
Durvena, Inc
04.2023 - Current
- Company Overview: Durvena is commercializing a point of care medical device that uses photochemical tissue passivation (PTP) to strengthen veins used during coronary bypass surgery to reduce graft failure
- This novel technology was developed at the Wellman Center of Photomedicine, a joint venture of Mass General Hospital and Harvard Medical Center
- Raised initial capital to fund early product development and testing
- Completed GLP large animal study proving efficacy of treatment on vein grafts
- Managed entire process of verification, validation and sterilization of first product build for first in human implants
- Completed human safety study with 30day and 6-month endpoints
- Communicated with FDA to solidify animal study protocol and 510k regulatory pathway through CBER (Center for Biologics Evaluation and Research)
- Durvena is commercializing a point of care medical device that uses photochemical tissue passivation (PTP) to strengthen veins used during coronary bypass surgery to reduce graft failure
- This novel technology was developed at the Wellman Center of Photomedicine, a joint venture of Mass General Hospital and Harvard Medical Center
Chief Executive Officer
Synexis LLC
08.2015 - 04.2023
- Company Overview: Synexis is the sole developer of innovative Dry Hydrogen Peroxide (DHP), which fights viruses, bacteria, mold, odors, and more in healthcare setting
- This technology works continuously both in the air and on surfaces without anyone having to leave the room, making us pioneers in microbial reduction
- Raised over $85M of outside capital including $57M from large strategic
- Hired executive team including CFO, COO and VP Marketing
- Signed partnership with large strategic partner including $60MM in minimum purchases over 3 years
- Negotiated manufacturing and supplier contracts
- Grew business to $5M in year 1 to ~$40M in year 3
- Successfully submitted FDA 510K
- Negotiated contracts with multiple strategic partners
- Built and manage team of over 100 employees
- Lead project team to develop 3 new commercial products in the Indoor Air Quality/Healthcare market
- Synexis is the sole developer of innovative Dry Hydrogen Peroxide (DHP), which fights viruses, bacteria, mold, odors, and more in healthcare setting
- This technology works continuously both in the air and on surfaces without anyone having to leave the room, making us pioneers in microbial reduction
Vice President Commercial Operations
Endoshape
01.2014 - 08.2015
- Company Overview: EndoShape, Inc
- Develops minimally invasive medical devices for peripheral vascular and neuro vascular uses in the interventional radiology market that will substantially replace existing technology
- Developed initial launch and pricing strategy for novel biocompatible vascular coil
- Provided market feedback to R and D team on product improvements
- EndoShape, Inc
- Develops minimally invasive medical devices for peripheral vascular and neuro vascular uses in the interventional radiology market that will substantially replace existing technology
Vice President, Sales
iDEV tECHNOLOGies
02.2006 - 01.2014
- Company Overview: IDev Technologies, Inc
- ('IDEV') is an Innovator and Developer of next generation minimally invasive medical devices for the treatment of peripheral vascular disease (PVD)
- PVD is currently treated by interventional physicians
- Played key role in raising over $60M in outside capital
- Developed and executed system to influence all aspects of the commercial plan, including product development, business development, aggressiveness of sales, manufacturing, spend and funding plans
- Involved in all aspects of FDA approval for vascular stent
- Built team of 2 US Sales Directors, 55 US sales reps, 1 EU sales Director, 8 direct reps and 1 country manager for Germany
- Developed and implemented successful pricing and launch strategy for 3 product lines in 3 years
- Consistently achieved revenue targets since initial product launch Jan 2008
- Increased revenue from $0 to over $35MM and average selling price over 20%
- Developed compensation plans for both US and EU sales teams
- Negotiated distributor contracts for Canada and Europe
- Transitioned IDEV product knowledge to Abbot Vascular sales team after acquisition
- IDev Technologies, Inc
- ('IDEV') is an Innovator and Developer of next generation minimally invasive medical devices for the treatment of peripheral vascular disease (PVD)
- PVD is currently treated by interventional physicians
Area Sales Director
FOXHOLLOW TECHNOLOGIES
04.2004 - 05.2006
- Company Overview: FoxHollow Technologies, Inc., manufactures medical devices used to treat peripheral artery disease, marketing its technology under the name 'SilverHawk Plaque Excision System.' The single-use device is sold to hospitals through a direct sales force and used by interventional cardiologists, vascular surgeons, and interventional radiologists
- Responsible for managing and motivating 54 District Sales Managers and Regional Managers generating $40+ million in annual business
- Managed hiring process for 65 Sales Professionals in Q4 2005
- Presented Foxhollow value presentation to hospital executives including CEO and CFO
- Developed 6 Sales Professionals to Regional Sales Manager position
- Company revenues exceeded $160 million in the first two years of commercialization
- FoxHollow Technologies, Inc., manufactures medical devices used to treat peripheral artery disease, marketing its technology under the name 'SilverHawk Plaque Excision System.' The single-use device is sold to hospitals through a direct sales force and used by interventional cardiologists, vascular surgeons, and interventional radiologists
Sales Representative - Coronary
MEDTRONIC/AVE
01.2001 - 04.2004
- Achieved 106% of plan
Education
B.S. - Organizational Communications with Marketing Minor
Missouri State University
Springfield, MOSkills
- Organizational Leadership
- Executive Leadership
- Risk Management
- Staff Management
- Strategic Visioning
- Strategic Partnerships
Timeline
Chief Executive Officer
Durvena, Inc
04.2023 - Current
Chief Executive Officer
Synexis LLC
08.2015 - 04.2023
Vice President Commercial Operations
Endoshape
01.2014 - 08.2015
Vice President, Sales
iDEV tECHNOLOGies
02.2006 - 01.2014
Area Sales Director
FOXHOLLOW TECHNOLOGIES
04.2004 - 05.2006
Sales Representative - Coronary
MEDTRONIC/AVE
01.2001 - 04.2004
B.S. - Organizational Communications with Marketing Minor
Missouri State University
Similar Profiles
Josh AndrievkJosh Andrievk
Staff Accounant at Jani-KingStaff Accounant at Jani-King
Rich DevineRich Devine
Head Baseball Coach at Shawnee Mission EastHead Baseball Coach at Shawnee Mission East
Cory MillerCory Miller
National Account Executive at Clore AutomotiveNational Account Executive at Clore Automotive
Kylie MillarKylie Millar
Executive Assistant to Chief Executive Officer, Vice President Corporate and Chief Risk Officer at Toyota Finance Australia LimitedExecutive Assistant to Chief Executive Officer, Vice President Corporate and Chief Risk Officer at Toyota Finance Australia Limited
JULIE FORRESTJULIE FORREST
Executive Assistant - Chief Marketing Officer and Chief Technology Officer at PLEXUS WORLDWIDEExecutive Assistant - Chief Marketing Officer and Chief Technology Officer at PLEXUS WORLDWIDE